Surgeons at Austin Hospital in Melbourne are using advanced machine perfusion technology to keep donor kidneys and livers biologically active outside the human body, a development that is reshaping how transplant medicine works and potentially expanding the pool of viable organs available to patients like Frank Giamarelos.
When Frank Giamarelos arrived at Austin Hospital, the kidney and liver waiting for him were no longer inside a human body — yet they were still alive. The organs had been sustained using machine perfusion technology, a medical advance that circulates warm, oxygenated blood or preservation fluid through donor organs, keeping them metabolically active for hours beyond what was previously possible.
Traditionally, transplant surgeons relied on cold storage to preserve donor organs — a technique that simply slows biological processes and offers a narrow window, often just a few hours, before an organ becomes unusable. Machine perfusion, by contrast, actively maintains organ function, allowing medical teams more time to assess viability, transport organs over greater distances, and potentially repair damage before transplantation.
The technology has been described by clinicians as bordering on science fiction. Machines can now sustain a liver or kidney in a near-normal physiological state — pumping nutrients and oxygen through tissue, clearing waste products, and even allowing doctors to test organ function before it ever enters a recipient's body.
For patients on Australia's transplant waiting lists, the implications are significant. According to the Organ and Tissue Authority, more than 1,700 Australians are currently awaiting a transplant. A persistent challenge has been that many donated organs are deemed unsuitable for transplantation using conventional cold storage methods — particularly those from older donors or donors with underlying health conditions. Machine perfusion may allow some of these previously discarded organs to be rehabilitated and used.
Austin Hospital has been among the leading Australian centres adopting these techniques, building on international research that has demonstrated improved outcomes in liver and kidney transplants when machine perfusion is used. Clinical trials in Europe and North America have shown lower rates of delayed graft function — where a transplanted organ is slow to begin working — in patients who received machine-perfused organs compared to those preserved by cold storage alone.
The technology is not without cost. Machine perfusion devices require significant capital investment and trained personnel to operate around the clock. Health economists and hospital administrators are weighing whether the improved outcomes justify the expense within constrained public health budgets.
Nonetheless, proponents argue the calculus is straightforward: if machine perfusion enables even a fraction of currently discarded organs to be safely transplanted, the reduction in patient deaths and the cost savings from fewer patients deteriorating on waiting lists could outweigh the upfront investment.
For patients like Giamarelos, the technology is less a matter of economics than of survival. The organs kept alive by machines outside a human body represent a convergence of engineering and biology that, until recently, existed only in the realm of speculation.
Analysis
Why This Matters
- Thousands of Australians and hundreds of thousands of people globally wait for donor organs each year; technology that expands the usable organ pool could directly save lives.
- Machine perfusion may reduce the geographic constraint on organ donation, allowing organs to travel further between donor and recipient hospitals.
- The shift raises new questions about healthcare funding priorities and how public hospitals invest in expensive but potentially life-saving equipment.
Background
Organ transplantation has faced a fundamental supply problem since its earliest days. The demand for donor organs has consistently outstripped supply, with waiting list deaths a grim measure of the gap. Cold ischaemic storage — packing organs in ice — became the standard preservation method in the latter half of the 20th century, but it is a blunt instrument that simply slows cellular decay rather than preventing it.
Research into machine perfusion began decades ago but accelerated significantly in the 2000s and 2010s as engineering advances made portable, reliable perfusion devices feasible. Early clinical trials in Europe demonstrated that normothermic machine perfusion — keeping organs at body temperature with oxygenated blood — could reduce injury and improve transplant outcomes compared to static cold storage.
Australia has been a relatively early adopter of the technology compared with many peer nations, with transplant centres in Melbourne and Sydney investing in perfusion devices and building clinical expertise. The field has moved quickly from experimental to standard-of-care at leading centres.
Key Perspectives
Transplant clinicians: Surgeons and hepatologists at centres like Austin Hospital argue machine perfusion is a genuine paradigm shift, enabling organ assessment before transplant and the use of marginal organs that would otherwise be discarded. They cite improved graft function and patient outcomes as compelling evidence.
Health system administrators: Hospital executives and health economists acknowledge the clinical promise but note that perfusion machines represent a significant cost, require 24-hour staffing, and must compete for funding against other pressing needs. They are watching long-term outcome data to justify broader rollout.
Critics/Skeptics: Some researchers caution that the evidence base, while growing, remains limited in scale and follow-up duration. They also note that machine perfusion addresses supply-side constraints but does not solve the underlying shortage of organ donors — a challenge that requires public education and systemic change.
What to Watch
- Publication of long-term outcome data from Australian and international machine perfusion trials, which will shape whether the technology becomes universally adopted or remains confined to specialist centres.
- Federal and state health budget decisions regarding funding for perfusion equipment at regional and smaller metropolitan hospitals.
- Changes to organ donation consent frameworks in Australia, which could interact with machine perfusion to further expand the viable organ pool.